The Analyst Verdict: Septerna In The Eyes Of 6 Experts
6 analysts have shared their evaluations of Septerna (NASDAQ:SEPN) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $34.67, a high estimate of $43.00, and a low estimate of $28.00. Marking an increase of 40.54%, the current average surpasses the previous average price target of $24.67.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of Septerna among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $35.00 | $30.00 |
| Catherine Novack | Jones Trading | Announces | Buy | $43.00 | - |
| Martin Auster | Raymond James | Announces | Strong Buy | $38.00 | - |
| Srikripa Devarakonda | Truist Securities | Announces | Buy | $34.00 | - |
| Derek Archila | Wells Fargo | Raises | Overweight | $28.00 | $18.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $30.00 | $26.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Septerna. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Septerna compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Septerna's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
To gain a panoramic view of Septerna's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Septerna analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Septerna: A Closer Look
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
A Deep Dive into Septerna's Financials
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Septerna displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 12113.07%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Septerna's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.02% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Septerna's ROE excels beyond industry benchmarks, reaching 2.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Septerna's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.6%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.